evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

539 questions · 553 findings · 58 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 37 · 6.7%GRADE not reported 8 · 1.4%Very low 27 · 4.9%Low 161 · 29.1%Moderate 219 · 39.6%High 101 · 18.3%

Summary of findings table ‐ immunostimulant vs placebo

Number of participants requiring antibiotics · adults with chronic bronchitis or chronic obstructive pulmonary disease

Summary of findings table ‐ immunostimulant probably leads to lower number of participants requiring antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ immunostimulant vs placebo

Side effects or other adverse events · adults with chronic bronchitis or chronic obstructive pulmonary disease

Summary of findings table ‐ immunostimulant showed no clear difference in adverse events/side effects compared with placebo (high certainty).

1 finding from 1 review

Macrolides vs placebo

Severe exacerbations requiring hospitalisation over the study period · adults and children with chronic asthma

Macrolides showed no clear difference in exacerbation requiring hospitalisation Weighted mean study duration:… compared with placebo (moderate certainty).

1 finding from 1 review

Macrolides vs placebo

Severe exacerbations (requiring ED visits or systemic steroids, or both) Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. Classification varied across studies. Weighted mean study duration: 35 weeks · adults and children with chronic asthma

Macrolides probably leads to lower severe exacerbations (requiring ED visits or systemic steroids, or… compared with placebo (moderate certainty).

1 finding from 1 review

Macrolides vs placebo

Serious adverse events (including mortality) · adults and children with chronic asthma

Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL13 or anti‐IL4 agents vs placebo

Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma

Anti‐IL13 or anti‐IL4 agents probably leads to lower exacerbation requiring hospitalisation or ED visit compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL13 or anti‐IL4 agents vs placebo

Rate of exacerbations requiring systemic corticosteroids · people with asthma

Anti‐IL13 or anti‐IL4 agents showed no clear difference in exacerbation requiring OCS (rate ratio) compared with placebo (low certainty).

1 finding from 1 review